Universal Plasmids The Unmet Goal

[THEO] Okay, picture this. You've got a piece of DNA — a plasmid, a little circle of genetic code — and you want to put it into a cell so the cell does something new. Make a drug, glow red, secrete a nanobody. Simple ask, right?

[DR. MARA] In one organism, maybe. The trouble is that a plasmid that works beautifully in one host can do absolutely nothing in the next one over.

[THEO] Right, and that's the whole subject today — the dream of a plasmid that goes anywhere. A cassette you could drop into a fungus, a probiotic, a diatom, and it just... works.

[DR. MARA] Let me define the problem for anyone coming from outside microbiology, because it's more layered than it sounds. A plasmid has to do a few distinct jobs. First, it has to get in — transformation, electroporation, or conjugation depending on the organism. Second, it has to persist. Either it integrates into the chromosome, or it replicates on its own as a free-standing episome, which requires an origin of replication the host actually recognizes.

[THEO] And that origin is the picky part.

[DR. MARA] Extremely picky. The replication machinery of a filamentous fungus doesn't look at a bacterial origin and know what to do with it. And even if the plasmid replicates, the third job is expression — the host has to transcribe your gene, splice it if there's an intron, translate it, and not chew up the protein. Every one of those steps is a place where "universal" breaks down.

[THEO] So when we say a plasmid "goes anywhere," we're really asking a lot of one little circle.

[DR. MARA] We are. And the story of how the field chased that starts, honestly, by accident.

[THEO] This is 1991, the fungus Aspergillus nidulans.

[DR. MARA] Gems and colleagues. They were re-isolating from a gene bank and pulled out a 6.1-kilobase insert they named AMA1. And this fragment boosted transformation of A. nidulans about 250-fold.

[THEO] 250 times. That's not a nudge, that's a different regime.

[DR. MARA] The reason was the interesting part. Normally, getting a plasmid into a filamentous fungus meant hoping it integrated into the chromosome — rare, inefficient. AMA1 let the plasmid stay free-form. Episomal. Maintained at ten to thirty copies per cell without integrating.

[THEO] So AMA1 is basically a fungal origin of replication that the cell recognizes as "yes, copy this."

[DR. MARA] That's the function, yes. And the part that made people sit up — it worked across the genus. Active in A. niger and A. oryzae, not just nidulans. That's the first real whisper of portability. One element, several hosts.

[THEO] Which plants the flag. The dream is on the board. But it's a fungal element in fungi that are pretty closely related, right? Same neighborhood.

[DR. MARA] Correct, and that's the honest limit of it. Cross-genus within Aspergillus is a long way from "anywhere." But it established the concept that an episomal replicator could be portable at all.

[THEO] Then jump to 2010 and you see the other wall — expression. This is the mushroom fungus, Coprinopsis cinerea.

[DR. MARA] Collins and colleagues built modular vectors — a multiple cloning site, an optional 5-prime intron, the kind of toolkit you'd want. And they got DsRed and mRFP to express. First time for those red fluorescent proteins in that system.

[THEO] The glow worked.

[DR. MARA] The glow worked. But GUS and luciferase — two absolutely standard reporters everywhere else — failed. Even with the intron added, which is often the fix for fungal expression problems.

[THEO] So it's not a getting-in problem, it's a... the-gene-is-in-but-nothing-comes-out problem.

[DR. MARA] Some barrier after splicing. They couldn't fully pin it, but the lesson lands hard: expression requirements are not universal. A plasmid can replicate perfectly and your reporter still gives you nothing. AMA1 solved persistence; this said persistence isn't enough.

[THEO] That's a real tension between the two papers, right? '91 says "look how portable the replication is," 2010 says "sure, but the payload might just sit there dead."

[DR. MARA] They don't contradict — they're complementary cautions. Different jobs failing.

[THEO] Okay, 2018, we leave fungi entirely. Lactic acid bacteria. Anik Debnath in the Church lab.

[DR. MARA] This is where the field gets deliberate about portability instead of lucky. Debnath wanted probiotic Lactobacillus — the live biotherapeutic idea, engineer a bug you actually eat to make a drug in your gut.

[THEO] Nanobodies. VHH — the little single-domain antibodies from camelids.

[DR. MARA] Right. And to make Lactobacillus secrete them, he needed a whole integrated set of parts. A broad-host plasmid. A first-in-LAB aTc-inducible promoter, so you can switch expression on. And here's the clever move — signal peptides derived from the strain's own exoproteome.

[THEO] Meaning he looked at what proteins the bug already secretes naturally, and borrowed those export tags.

[DR. MARA] Metagenomics-guided, strain-specific consensus signal peptides. Instead of forcing a generic tag and hoping, he read the organism's own preferences. And it worked — over 10 micrograms per milliliter of anti-gp120 and anti-TNF-alpha VHH, from two different Lactobacillus species, with neutralization within two percent of conventionally made antibody.

[THEO] So this is the answer to the 2010 problem. If expression isn't universal, stop pretending it is — mine the host's own machinery.

[DR. MARA] That's exactly the through-line. Portability stops meaning "one part fits all" and starts meaning "a design strategy that adapts to each host." That's the maturation.

[THEO] Then 2020 goes big. Like, forty-four-kilobase big.

[DR. MARA] The mitochondrial genome of the diatom Thalassiosira pseudonana. Nearly 43,827 base pairs, assembled in baker's yeast from twelve overlapping PCR fragments, then moved into E. coli as a shuttle.

[THEO] Yeast is the great assembler, E. coli is the workhorse copier. Classic hand-off.

[DR. MARA] And E. coli carried it with no growth burden, which is impressive at that size. But — after about sixty generations, five of thirty clones had deleted a diagnostic chunk. Seventeen percent instability.

[THEO] And the culprit?

[DR. MARA] GC content. This diatom genome is around 30 percent G-plus-C. The higher-GC Phaeodactylum genome, zero deletions over the same window. So the DNA sequence itself — its base composition — determines whether your host tolerates it.

[THEO] That's a new failure mode entirely. Not getting in, not expressing — just quietly falling apart because the host doesn't like AT-rich DNA.

[DR. MARA] It reframes "goes anywhere." A plasmid isn't only a functional unit, it's a physical molecule the host has to hold onto faithfully. Composition is portability too.

[THEO] And the last one, 2023, isn't even about the host — it's about the shelf.

[DR. MARA] Lipid nanoparticles. Delivery vehicles for mRNA and DNA. The finding is almost mundane and completely practical: freeze them without sugar and they fuse into these collapsed donut-shaped ghosts. Twelve percent sucrose prevents it. And DNA cargo survives storage far better than mRNA.

[THEO] Which closes the loop, doesn't it? We spent thirty years on "will it replicate, will it express, will it stay intact" — and this says none of that matters if the thing dies in the freezer on the way to a patient.

[DR. MARA] Portability all the way to the point of use. That's where the field is heading — treating every step, molecule to fridge to cell, as part of "anywhere."

[THEO] From a lucky 6.1-kb accident to designing for the whole journey. Not bad. We'll pick up the mailbag after the break.